{'52WeekChange': -0.5706941,
 'SandP52WeekChange': None,
 'address1': '520 U.S. Highway 22',
 'address2': 'Suite 305',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 1.65,
 'askSize': 21500,
 'averageDailyVolume10Day': 2135725,
 'averageVolume': 5264747,
 'averageVolume10days': 2135725,
 'beta': None,
 'beta3Year': None,
 'bid': 1.64,
 'bidSize': 3000,
 'bookValue': 1.131,
 'category': None,
 'circulatingSupply': None,
 'city': 'Bridgewater',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 1.7,
 'dayLow': 1.63,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.638,
 'enterpriseToRevenue': 93.7,
 'enterpriseValue': 176624688,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 1.8765714,
 'fiftyTwoWeekHigh': 7.48,
 'fiftyTwoWeekLow': 1,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 114904275,
 'forwardEps': -0.46,
 'forwardPE': -3.5652173,
 'fromCurrency': None,
 'fullTimeEmployees': 180,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.04617,
 'heldPercentInstitutions': 0.14269,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/menlotherapeutics.com',
 'longBusinessSummary': 'Menlo Therapeutics Inc., a pharmaceutical company, '
                        'focuses on developing and commercializing various '
                        'therapeutics for dermatology. It offers AMZEEQ, a '
                        'topical minocycline used for the treatment of '
                        'inflammatory lesions of non-nodular '
                        'moderate-to-severe acne vulgaris in patients 9 years '
                        'of age and older. The company is also developing '
                        'FMX103, which is in Phase III clinical trials for the '
                        'treatment of moderate-to-severe papulopustular '
                        'rosacea in adults; and FCD105, a topical combination '
                        'foam that is in Phase II clinical trials for the '
                        'treatment of moderate-to-severe acne vulgaris. In '
                        'addition, it is developing Serlopitant, a once-daily '
                        'oral NK1 receptor antagonist, used as a treatment '
                        'option for pruritus associated with prurigo '
                        'nodularis. The company was founded in 2003 and is '
                        'headquartered in Bridgewater, New Jersey.',
 'longName': 'Menlo Therapeutics Inc.',
 'market': 'us_market',
 'marketCap': 274900064,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_6511914',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -120207000,
 'nextFiscalYearEnd': 1640908800,
 'open': 1.67,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 0.01,
 'phone': '800-775-7936',
 'previousClose': 1.67,
 'priceHint': 4,
 'priceToBook': 1.4500442,
 'priceToSalesTrailing12Months': 145.83557,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 1.7,
 'regularMarketDayLow': 1.63,
 'regularMarketOpen': 1.67,
 'regularMarketPreviousClose': 1.67,
 'regularMarketPrice': 1.67,
 'regularMarketVolume': 1421197,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 167622000,
 'sharesPercentSharesOut': 0.0671,
 'sharesShort': 11239221,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 4791331,
 'shortName': 'Menlo Therapeutics Inc.',
 'shortPercentOfFloat': 0.0787,
 'shortRatio': 1.62,
 'startDate': None,
 'state': 'NJ',
 'strikePrice': None,
 'symbol': 'MNLO',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.008,
 'twoHundredDayAverage': 2.911439,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '6b490a10-8f59-3eaa-bfc0-844d4993c363',
 'volume': 1421197,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.menlotherapeutics.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '08807'}